Compositions containing Lactobacillus crispatus bacterial lysate and / or bacteria for improving skin conditions

Lactobacillus crispatus lysate addresses the need for a safe, effective topical treatment by reducing skin irritation and inflammation and promoting collagen biosynthesis to improve skin health and appearance.

JP2024543626APending Publication Date: 2024-11-21BIOTIX PTE LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024534222
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-10
Filing Date
2022-12-09
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current treatments for skin disorders such as irritant contact dermatitis, atopic dermatitis, psoriasis, and atopic eczema often have significant side effects, and there is a need for a safer, effective topical treatment that can improve skin health, reduce inflammation, and prevent or reverse skin aging.

Method used

Topical application of Lactobacillus crispatus lysate or active fractions to promote skin health, reduce inflammation, and prevent or reverse skin aging by stimulating anti-inflammatory pathways and collagen biosynthesis.

Benefits of technology

L. crispatus lysate effectively reduces skin irritation, inflammation, and aging symptoms by enhancing skin barrier function and collagen production, improving skin appearance and health without causing adverse effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543626000001_ABST
    Figure 2024543626000001_ABST
Patent Text Reader

Abstract

Disclosed herein are compositions comprising bacterial lysates and / or bacteria for improving skin conditions.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to compositions comprising bacterial lysates and / or bacteria. The compositions are suitable for topical application and may find use in improving the appearance of skin, improving skin health, preventing or treating skin inflammation, preventing skin aging, and / or slowing or reversing the characteristics of skin aging. [Background technology]

[0002] The skin constitutes a barrier against external insults, and the quality of this barrier can be affected by external irritant agents (e.g. surfactants, acids, bases, oxidants, reducing agents, concentration solvents, gases or toxic fumes), mechanical stresses (e.g. friction, impact, abrasion, surface breaks, dust projection, particle projection, shaving or hair removal), or thermal or climatic instability (e.g. cold and dryness). These and other environmental factors can lead to skin irritation and inflammation, which can be unpleasant, disruptive and painful.

[0003] Skin irritation is conventionally defined as a local reversible inflammatory reaction, characterized by edema and erythema, induced by single or repeated contact of the skin with a chemical substance. Substances belonging to different classes of very different chemical products, such as keratinic solvents, dehydrating agents, or oxidizing or reducing agents, can be considered as irritants. Skin irritation is a very serious phenomenon, representing approximately 60% to 80% of clinical cases of non-allergic contact dermatitis.

[0004] Irritant contact dermatitis (ICD) can be defined as acute or chronic. Acute ICD is, as a rule, characterized by inflammation, whereas chronic ICD is characterized by keratinocyte hyperproliferation and transient hyperkeratosis. The biochemical events involved in skin irritation are complex and relatively poorly described. Upon contact between an irritant and the skin, the first cells to be damaged and activated by the chemical product are the keratinocytes. Through the release of many mediators and cytokines, keratinocytes play an essential role in initiating the inflammatory skin response, which underlies the entire cascade of inflammation and ultimately manifests the clinical signs of ICD.

[0005] Atopic dermatitis, also known as eczema and atopic eczema, is one of the most common inflammatory disorders, affecting up to 20% of children and 10% of adults in high-income countries. The disorder is characterized by intense itching (pruritus) and recurrent eczematous lesions. Atopic dermatitis has a heterogeneous clinical presentation. The causes of atopic dermatitis are complex and multifactorial. There is a strong genetic component, and evidence for multiple mechanisms of genetic risk. Loss-of-function mutations in the gene encoding filaggrin (FLG) are the strongest and most consistently reported genetic variants, supporting a highly potent role for filaggrin as a major structural protein in the epidermis. Although genetics are important in atopic dermatitis, the increasing global prevalence of the disorder highlights the role of environmental factors. Individuals with atopic dermatitis are at increased risk for asthma, allergic rhinitis, and food allergies, and may also be at increased risk for a wide range of health and psychosocial outcomes. It has been widely reported that atopic eczema skin can be affected by an imbalanced skin microbiome population (dysbiosis). For example, the skin of atopic eczema patients can be enriched with the pro-inflammatory microorganism Staphylococcus aureus, which promotes the initiation and exacerbates the skin flares associated with the condition.

[0006] Psoriasis is a common skin disease affecting approximately 25 million people in North America and Europe, and is probably the most prevalent immune-mediated skin disease in adults. It is an autoimmune disease affecting the skin, triggered by an abnormally activated cellular immune system, and similar to other immune-mediated disorders such as Crohn's disease, rheumatoid arthritis, multiple sclerosis, and juvenile diabetes. The immunopathogenesis of psoriasis involves both skin cells, keratinocytes, and immune cells, including dendritic cells, T cells, and in particular the T(h) helper 17 pathway. The main clinical symptoms exhibited by patients affected by psoriasis include erythema (rash caused by damaged and / or inflamed capillaries), induration, skin thickening, scaling, itching / pruritus, and / or stinging.

[0007] Skin inflammatory conditions, such as ICD, psoriasis and atopic eczema, are usually treated with topical corticosteroids as first-line treatment.However, these commonly used topical therapies can have significant side effects, including skin thickening, atrophy, striae, rosacea, perioral dermatitis, acne, purpura, hirsutism, pigmentation changes, delayed wound healing, and exacerbation of skin infections.Individuals who are unresponsive to topical therapy may undergo systemic treatment with antibodies targeting TNF-α, interleukin (IL-) 23, IL-17, and IL-13 receptors.However, systemic treatment also shows significant side effects, including opportunistic infections, itching, and rashes. Summary of the Invention

[0008] The present invention was conceived in view of the above considerations, in particular the need for effective topical active ingredients with a better safety profile for use in preventing or treating skin disorders or reducing the severity of symptoms associated with skin disorders.

[0009] Summary of the Invention The inventors found that healthy individuals have higher levels of probiotic Lactobacillus crispatus on the skin compared to individuals suffering from skin disorders. The inventors also found that L. crispatus lysate has anti-inflammatory and skin protective effects that may prevent or treat skin inflammation when applied to a subject. Furthermore, L. crispatus lysate has been found to have anti-inflammatory effects on the mucous membranes of the vagina and penis, particularly the glans penis. The inventors further found that the levels of probiotic L. crispatus decrease with age, and as such, it is possible to prevent or delay skin aging or reduce the apparent age of the skin using a composition containing L. crispatus or L. crispatus lysate. Thus, the present invention provides compositions for topical administration and cosmetic and clinical uses of said compositions to prevent and treat skin inflammation, improve skin health, prevent or reduce pruritus, prevent or treat genital irritation, including vaginitis and balanitis, improve the appearance of the skin, prevent or delay skin aging, or reduce the apparent age of the skin.

[0010] Thus, in a first aspect, the present invention provides: i) a lysate of Lactobacillus crispatus or an active fraction thereof; and / or ii) Lactobacillus crispatus population A topical composition comprising:

[0011] The lysate, active fraction and / or population may be present in an amount effective to improve the appearance of the skin, improve the health of the skin, prevent or treat skin inflammatory disorders, prevent or treat skin irritation, prevent or reduce pruritus, prevent or treat genital irritation, including vaginitis and balanitis, treat or prevent acne, retard or prevent skin aging, or reduce the apparent age of the skin, compared to the skin before administration of the composition. Additionally or alternatively, the lysate, active fraction and / or population of L. crispatus may be present in an amount effective to treat irritant skin diseases, prevent or reduce pruritus, prevent or treat genital irritation, including vaginitis and balanitis, dermatitis, and inflammatory skin disorders. For example, the formulation comprises these active ingredients in an amount effective to treat conditions such as irritant contact dermatitis, atopic dermatitis, eczema, atopic eczema, psoriasis, pruritus and / or skin irritation.

[0012] An effective amount of the L. crispatus population and / or L. crispatus lysate, or active fraction thereof, can be determined using functional assays. For example, an effective amount of the population, lysate, or active fraction can be selected based on an in vitro assay in which the population, lysate, or active fraction modifies expression of genes involved in one or more of collagen biosynthesis, collagen formation, extracellular matrix organisation, cholesterol regulation, cell junction organisation, collagen chain trimerisation, aryl-hydrocarbon signalling, and inflammation. In particular, the population, lysate, or active fraction can be present in an amount sufficient to stimulate the aryl-hydrocarbon-receptor pathway in vitro or in vivo, promote keratinocyte proliferation in vitro, and / or protect keratinocytes from stimulation-induced cell death in an in vitro stimulation model (e.g. as exemplified in Example 5).

[0013] The composition according to the first aspect may comprise one or more physiologically acceptable carriers, excipients, preservatives, fillers, anti-caking agents, anti-foaming agents, bulking agents, thickening agents, gelling agents, emulsifiers, surfactants, film formers, propellants, pH adjusters, neutralizing agents or stabilizing agents. One or more of these ingredients may be added to aid in the formulation of a suitable topical composition for application to a subject, such as a cream, lotion, gel, mousse, solid stick, spray, ointment, or milk.

[0014] A second aspect of the invention provides a cosmetic method that improves the appearance of the skin, improves the health of the skin, prevents or reduces skin irritation, delays or prevents skin aging, reduces or prevents acne, or reduces the apparent age of the skin, compared to the skin before administration of the composition. The cosmetic method comprises applying a composition according to the first aspect to the skin of a subject. In some embodiments, the skin may appear plumper, smoother, firmer, and / or more hydrated after administration of the composition. In some embodiments, the skin may appear less red, less flaky, less rough, and / or less wrinkled after administration of the composition. In some embodiments, the method comprises applying the composition every 1-7 days. In some embodiments, the method comprises applying the composition once a day. In some embodiments, the composition may be applied more than once a day, for example twice a day. In some embodiments, after 1 day to 14 weeks, the appearance of the skin will be improved, skin irritation will be reduced, and / or skin aging will be delayed, prevented, or reversed. In some embodiments, after 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, the appearance of the skin will be improved, skin irritation will be reduced, and / or skin aging will be slowed, prevented or reversed.

[0015] A third aspect of the invention provides a composition according to the first aspect of the invention for use in a therapeutic method to improve the appearance of the skin, improve the health of the skin, prevent or treat skin irritation, prevent or reduce pruritus, prevent or treat genital irritation including vaginitis and balanitis, treat or prevent acne, delay or prevent skin aging, or reduce the apparent age of the skin compared to the skin before administration of the composition. Additionally or alternatively, the composition may be used to treat inflammatory skin conditions, irritant skin diseases and / or dermatitis, such as irritant contact dermatitis, atopic dermatitis, eczema, atopic eczema, psoriasis, pruritus and / or skin irritation. The method comprises applying the composition to the skin of a subject in need thereof. In some embodiments, the skin irritation may be caused by inflammatory skin irritation, irritant contact dermatitis, atopic dermatitis, eczema, atopic eczema, and / or psoriasis. In some embodiments, the method comprises applying the composition every 1-7 days. In some embodiments, the method includes applying the composition once a day. In some embodiments, the composition may be applied more than once a day, for example twice a day. In some embodiments, after 1-14 weeks, the skin's appearance will be improved, skin irritation will be reduced, pruritus will be reduced, genital irritation will be reduced, symptoms of balanitis or vaginitis will be reduced, and / or skin aging will be delayed, prevented or reversed. In some embodiments, after 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, the skin's appearance will be improved, skin irritation will be reduced, pruritus will be reduced, genital irritation will be reduced, symptoms of balanitis or vaginitis will be reduced, and / or skin aging will be delayed, prevented or reversed.

[0016] A fourth aspect of the invention provides a method of treating inflammatory skin disorders, irritant skin diseases, pruritus, genital irritation, balanitis, vaginitis, and / or dermatitis, such as irritant contact dermatitis, atopic dermatitis, eczema, atopic eczema, psoriasis, and / or skin irritation caused by inflammatory skin irritants, improving skin health, preventing or treating skin irritation, treating or preventing acne, slowing skin aging, and / or reversing skin aging in a subject, the method comprising administering to the subject a composition according to the first aspect.

[0017] In some embodiments of the cosmetic method of the second aspect, the composition for use according to the third aspect, or the method for treating a subject according to the fourth aspect, the composition may modify expression of genes involved in one or more of collagen biosynthesis, collagen formation, extracellular matrix organization, collagen chain trimerization, aromatic hydrocarbon signaling, anti-apoptotic molecules, cell proliferation and inflammation.

[0018] In some embodiments of the cosmetic method of the second aspect, the composition for use according to the third aspect, or the method for treating a subject according to the fourth aspect, the composition increases expression of genes involved in one or more of collagen biosynthesis, collagen formation, extracellular matrix organization, collagen chain trimerization, aromatic hydrocarbon signaling, anti-inflammatory or anti-apoptotic molecules, and / or decreases expression of pro-inflammatory molecules.

[0019] In some embodiments of the cosmetic method of the second aspect, the composition for use according to the third aspect, or the method for treating a subject according to the fourth aspect, the composition activates the aromatic hydrocarbon receptor pathway.

[0020] In a fifth aspect, a method is provided for modifying expression of genes involved in one or more of collagen biosynthesis, collagen formation, extracellular matrix organization, collagen chain trimerization, aromatic hydrocarbon signaling, anti-apoptotic molecules, cell proliferation and inflammation in a subject. In some embodiments, the method activates the aromatic hydrocarbon receptor pathway in the subject. In some embodiments, the subject is a human. In some embodiments, the method is a therapeutic method. In some embodiments, the method is a cosmetic method. In some embodiments, the method treats inflammatory skin disorders, irritant skin diseases, pruritus, genital irritation, balanitis, vaginitis, and / or dermatitis, such as irritant contact dermatitis, atopic dermatitis, eczema, atopic eczema, psoriasis, and / or skin irritation caused by inflammatory skin irritants, improves skin health, prevents or treats skin irritation, treats or prevents acne, delays skin aging, and / or reverses skin aging in a subject.

[0021] The present invention includes combinations of the described embodiments and preferred features except where such combinations are clearly impermissible or clearly avoided. [Brief description of the drawings]

[0022] BRIEF DESCRIPTION OF THE DRAWINGS Embodiments and experiments illustrating the principles of the present invention will now be discussed with reference to the accompanying figures.

[0023] [Figure 1A] FIG. 1A shows the skin of a patient with atopic eczema and psoriasis, which has reduced levels of L. crispatus compared to the skin of a healthy individual. [Figure 1B] FIG. 1B shows that the population of L. crispatus present on the skin of healthy individuals decreases with age. [Diagram 2] FIG. 2 shows that L. crispatus regulates the expression of genes related to collagen biosynthesis, collagen formation, AhR signaling and inflammation. [Diagram 3]FIG. 3 shows that L. crispatus lysate positively regulates the aryl hydrocarbon receptor (AhR) pathway, causing increased expression of CYP1A1 and AhRR genes, which are under the direct control of AhR. [Figure 4A] FIG. 4A shows the results of an in vitro stimulation model demonstrating that L. crispatus lysate protects keratinocytes from stimulation-induced cell death. [Figure 4B] FIG. 4B shows that L. crispatus lysate provides superior protection of keratinocytes from irritant-induced cell death compared to other commonly used skin care actives. [Diagram 5] FIG. 5 shows that L. crispatus lysate protects healthy volunteers from SDS-mediated skin irritation and that L. crispatus lysate does not cause skin irritation. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0024] Aspects and embodiments of the present invention will now be discussed with reference to the accompanying figures. Further aspects and embodiments will be apparent to those skilled in the art. All documents mentioned in this text are incorporated herein by reference.

[0025] First-line corticosteroid treatments for inflammatory skin conditions such as ICD, psoriasis, and atopic eczema can have significant side effects, including skin atrophy, striae, rosacea, perioral dermatitis, acne, purpura, hirsutism, pigmentation changes, delayed wound healing, and exacerbation of skin infections. Similarly, systemic treatment with antibodies can also exhibit significant side effects, including infection, itching (pruritus), and rashes. As a result, there is a need for the development of safe and effective compositions to reduce skin irritation.

[0026] The present invention relates to the discovery that Lactobacillus crispatus (L. crispatus) colonizes the skin of healthy individuals and is reduced in individuals with skin inflammatory disorders, such as atopic eczema and psoriasis, and is reduced in elderly individuals, indicating that L. crispatus may play a role in maintaining normal skin health and that loss of commensal L. crispatus may contribute to skin aging. The present invention thus provides compositions for topical administration comprising L. crispatus populations and / or L. crispatus lysates to improve the appearance of the skin; improve skin health; prevent and / or treat skin inflammatory disorders; prevent or reduce pruritus, prevent or reduce genital irritation, prevent or reduce symptoms of balanitis or vaginitis, or prevent, delay and / or reverse skin aging.

[0027] L. crispatus is a common species of bacteria known to colonize the vagina and vertebrate gastrointestinal tract. To date, L. crispatus has been recognized as a useful probiotic for treating recurrent urinary tract infections in women. However, the use of L. crispatus lysates or the use of L. crispatus as a probiotic to improve skin appearance, treat skin inflammatory disorders, prevent or reduce pruritus, and / or prevent / reverse skin aging has not been reported previously. L. crispatus is publicly available from microorganism depositories such as ATCC, NCIMB, DSMZ, etc.

[0028] In some embodiments, the lysate of L. crispatus may be a total lysate, including intracellular components of the cells as well as the cell walls and membranes of the cells. Cell lysis may be performed by any suitable method, such as sonication, osmotic shock, heat shock, by ultrasound, mechanical disruption, such as French press, liquid homogenization, or centrifugation mechanical strain. In some embodiments, the lysate may be an active fraction of the lysate. The active fraction may include one or more isolated components of the lysate that, when applied to a subject as part of a topical composition, still improve the appearance of the skin, improve the health of the skin, prevent and / or treat skin inflammation, prevent or reduce skin pruritus, prevent or reduce genital irritation, prevent or reduce symptoms of balanitis or vaginitis, prevent or delay skin aging, or reduce the apparent age of the skin. For example, the active fraction may contain one or more metabolites, proteins, carbohydrates, nucleic acids, or lipids derived from the lysate. The active fraction of the lysate may also be a purified fraction that lacks one or more components of the total lysate, and when applied to a subject as part of a topical composition, still improves the appearance of skin, improves skin health, prevents and / or treats skin inflammation, prevents or reduces skin pruritus, prevents or reduces genital irritation, prevents or reduces symptoms of balanitis or vaginitis, prevents or slows skin aging, or reduces the apparent age of the skin.For example, the active fraction may be a total lysate from which one or more metabolites, proteins, carbohydrates, lipids, or nucleic acids (e.g., RNA or DNA) have been removed.Removal of DNA and / or RNA from the total lysate may be performed by any suitable technique known in the art, such as through precipitation, centrifugation, DNase treatment, and / or RNase treatment.

[0029] In some embodiments, the composition may comprise 0.0001% to 100%, 0.001% to 75%, 0.01% to 50%, or 0.1% to 25% by volume of L. crispatus lysate, or an active fraction thereof, based on the total weight of the composition. In some embodiments, the composition may comprise 0.0001% to 100%, 0.001% to 75%, 0.01% to 50%, or 0.1% to 25% by volume of L. crispatus lysate, or an active fraction thereof, based on the total volume of the composition. In some embodiments, the composition may comprise up to 1%, 2%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 90%, or 100% by weight or volume of L. crispatus lysate, or an active fraction thereof, based on the total weight of the composition. In some embodiments, the composition may comprise at least 1%, 2%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% by weight or volume of L. crispatus lysate, or an active fraction thereof.

[0030] In some embodiments, the lysate concentration per gram of composition is 10 2 ~10 11 , 10 5 ~10 10 , or 10 7 ~10 9 corresponds to the amount of lysate produced from an L. crispatus population equivalent to cfu / g.

[0031] In some embodiments, the composition comprises 10 2 ~10 11 cfu / g, 10 5 ~10 10 cfu / g, or 10 7 ~10 9It may contain L. crispatus at a concentration of cfu / g.

[0032] In some embodiments, the composition may comprise 0.0001% to 100%, 0.001% to 75%, 0.01% to 50%, or 0.1% to 25% by weight of L. crispatus population, based on the total weight of the composition. In some embodiments, the composition may comprise 0.0001% to 100%, 0.001% to 75%, 0.01% to 50%, or 0.1% to 25% by volume of L. crispatus population, based on the total volume of the composition. In some embodiments, the composition may comprise up to 1%, 2%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 90%, or 100% by weight or volume of the L. crispatus population, based on the total weight of the composition. In some embodiments, the composition may comprise at least 1%, 2%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% by weight or volume of the L. crispatus population.

[0033] In some embodiments, the composition may comprise a lysate, or an active fraction thereof, from an isolated strain of L. crispatus, such as L. crispatus strain VPI3199. In some embodiments, the lysate, or an active fraction thereof, may be from an isolated strain of L. crispatus, such as L. crispatus strain VPI3199. In some embodiments, the composition may comprise an isolated strain of L. crispatus, such as L. crispatus strain VPI3199. In some embodiments, the L. crispatus population is L. crispatus VPI3199. The L. crispatus VPI3199 strain is described in Lactobacillus crispatus (Brygoo and Aladame 1953) Moore and Holdeman (1970).

[0034] The compositions of the present invention comprise an effective amount of L. crispatus lysate or L. crispatus population to improve the appearance of skin, improve skin health, prevent or treat skin irritation, prevent or reduce skin pruritus, prevent or reduce genital irritation, prevent or reduce symptoms of balanitis or vaginitis, and / or prevent, slow or reverse skin aging. The compositions of the present invention may take any suitable form for topical administration and may include medicamentally or cosmetically suitable carriers, excipients, preservatives, fillers or stabilizers well known in the art. For example, the compositions may include one or more excipients selected from isopropanol, hydroxypropyl cellulose, glyceryl stearate, cetylstearyl alcohol, glycerol, cetyl alcohol liquid petrolatum, isopropyl myristate, methyl POB, propyl POB.

[0035] Suitable composition formulations for topical administration are well known in the art, and include cream, lotion, gel, mousse, solid stick, spray, ointment or milk.Suitable techniques for preparing such formulations are well known in the art, and can be found, for example, in Williams, D. and Schmitt, W., 1996. Chemistry and Technology of the Cosmetics and Toiletries Industry. Dordrecht: Springer Netherlands, Harry, R. and Rieger, M., 2000. Harry's cosmeticology. New York: Chemical Pub. Co., and Remington, J. and Gennaro, A., 2000. Remington the science and practice of pharmacy. Baltimore, Md.: Lippincott Williams & Wilkins.

[0036] The composition of the present invention may also contain other topically beneficial ingredients that can enhance or complement the activity of L. crispatus population, lysate or active fraction. The selection of additional topically beneficial ingredients depends on the intended use of the formulation and composition. Topically beneficial ingredients that are standard in the art can be found, for example, in Gottschalck, T. and McEwen, G., 2004. International cosmetic ingredient dictionary and handbook. Washington, DC: Cosmetic, Toiletry, and Fragrance Association.

[0037] Examples of topically useful ingredients that may be used in the compositions of the present invention include, but are not limited to: fragrances or essential oils; dyes or colorants; formulation aids such as anti-caking agents, anti-foaming agents, fillers and extenders, thickeners, gelling agents, structuring agents and emulsion stabilizers; surfactants and emulsifiers; film formers to enhance adhesion and retention on the intended target (e.g., skin); propellants, preservatives, and pH adjusters and neutralizing agents.

[0038] Other topically useful ingredients may provide additional benefits to the keratinous surface to which the composition will be applied (i.e., skin benefit agents, or active agents). These include, but are not limited to, astringents such as clove oil, menthol, camphor, eucalyptus oil, eugenol, methyl lactate, witch hazel, and the like. hazel distillates; antioxidants or free radical scavengers, such as ascorbic acid, its fatty esters and phosphates, tocopherol and its derivatives, N-acetylcysteine, xacid and lipoic acid; anti-acne agents, such as salicylic acid and benzoyl peroxide; anti-microbial or anti-fungal agents, such as caprylyl glycol, triclosan, phenoxyethanol, erythromycin, tolnaftate, nystatin or clotrimazole; chelating agents, such as EDTA; topical analgesics, such as benzocaine, lidocaine or procaine; anti-aging / anti-wrinkle agents, such as retinoids or hydroxy acids; skin whitening agents, such as licorice, ascorbyl phosphate, hydroquinone or kojic acid; skin conditioning agents, such as various and occlusive, humectants; anti-irritants, such as These supplemental skin benefit agents include, for example, cola, bisabolol, aloe vera, or panthenol; anti-inflammatory agents, such as hydrocortisone, clobetasol, dexamethasone, prednisone, acetylsalicylic acid, glycyrrhizic acid, or glycyrrhetinic acid; anti-cellulite agents, such as caffeine and other xanthines; humectants, such as alkylene polyols or hyaluronic acid; emollients, such as oily esters or petrolatum; sunscreens (organic or inorganic), such as avobenzone, oxybenzone, octyl methoxycinnamate, titanium dioxide, or zinc oxide; exfoliants (chemical or physical), such as N-acetylglucosamine, mannose phosphate, hydroxy acids, lactobionic acid, peach kernel, or sea salt; self-tanning agents, such as dihydroxyacetone; and biologically active peptides, such as palmitoyl pentapeptide or argireline. These supplemental skin benefit agents will be used in amounts that are normally known to be effective in order to be active when used for their intended purpose.

[0039] Healthy skin can be defined in comparison with diseased skin. Healthy skin is characterized by a fully formed and competent epidermal barrier. Characteristics of healthy skin include epidermal integrity, moisturization, high elasticity, functional wound healing, absence of itching, absence of inflammation, and absence of redness or erythema.

[0040] Skin health and appearance can be evaluated based on several physiological parameters, including hydration or dryness, transepidermal water loss (TEWL), erythema index, elasticity, laxity, skin friction, redness and scaling. Skin health and appearance can also be evaluated based on the presence or absence of symptoms of skin disorders (e.g., eczema, acne, rosacea), and the presence or absence of dark spots.

[0041] Improved skin health and appearance may be correlated with increased plumpness and / or smoothness, and may appear less wrinkled. Improved skin health and appearance may also be correlated with reduced dryness and / or roughness of the skin. Improved skin health and appearance may also be correlated with reduced redness intensity or rash intensity. Improved skin health and appearance may also be correlated with reduced number of wrinkles on the skin.

[0042] For example, a decrease in extracellular collagen in skin health can be associated with decreased skin hydration and skin aging. Loss of water from the outermost layer of the skin, the stratum corneum, can also lead to dysregulation of normal desquamation (the normal shedding of the outermost dead skin cells of the skin), leading to the visible appearance of dry and / or flaky skin, further affecting the physical appearance and health of the skin.

[0043] The compositions of the present invention may be capable of improving the appearance of the skin, improving the health of the skin, reducing or preventing inflammatory skin diseases, skin irritation, preventing or reducing skin pruritus, preventing or reducing genital irritation, preventing or reducing symptoms of balanitis or vaginitis, preventing or reversing skin aging, by modifying gene expression, for example, by modifying gene expression in epidermis, dermis, and / or cells of the immune system.For example, the compositions may increase or decrease gene expression upon topical administration to the skin.In particular, the compositions may modify the expression of genes associated with collagen biosynthesis, collagen formation, retinol biosynthesis, extracellular matrix organization, collagen chain trimerization, aromatic hydrocarbon signaling, and inflammation.

[0044] In some embodiments, the compositions of the present invention may contain a lysate, active fraction, or population in an amount sufficient to modify the expression of genes involved in one or more of collagen biosynthesis (e.g., retinoid acid receptor (RAC), cytochrome (CYPA1A1), and collagen genes, e.g., COL1, COL2), collagen formation, extracellular matrix organization, collagen chain trimerization, aromatic hydrocarbon signaling (e.g., AhR repressor), anti-apoptotic molecules, cell proliferation, and inflammation when applied to skin cells, keratinocytes, fibroblasts, or skin immune cells in vitro or in vivo. In particular, the lysate, active fraction, or population may be present in an amount sufficient to activate the aromatic hydrocarbon receptor pathway when applied to skin cells, keratinocytes, fibroblasts, and skin immune cells in vitro and in vivo. Gene expression may be measured using any standard technique known in the art, for example, gene expression may be determined using real-time PCR, northern blotting, western blotting, or DNA microarrays.

[0045] Collagen is particularly important in maintaining skin hydration and therefore in maintaining good skin health and appearance. Collagen is the most abundant component of the extracellular matrix and helps maintain the structure of the skin to support smooth, firm and strong skin. A decrease in collagen abundance correlates with a decrease in skin hydration, elasticity and density, and an increase in skin roughness and laxity, leading to the appearance of skin aging and / or a decrease in skin appearance and health. The composition can also prevent or reverse skin aging, improve skin appearance, and / or improve skin health by promoting collagen biosynthesis and collagen formation. For example, the composition can promote the expression of genes related to collagen biosynthesis and formation, and / or inhibit the expression of genes related to decreased collagen biosynthesis and formation. In particular, the composition can promote the expression of genes involved in retinol biosynthesis. Retinol promotes anti-aging effects by activating retinoid acid receptors (RAC) in the epidermis to induce the expression of genes such as CYPA1A1 (cytochrome) and collagen genes, such as COL1 and COL3. As a result, the composition may reduce the appearance or number of wrinkles and improve skin elasticity.

[0046] The abundance of collagen in the extracellular matrix of the skin may decrease with age. The decrease in collagen abundance in the skin may be accompanied by changes in the physical appearance of the skin, including skin that is more wrinkled, less elastic, more loose, less hydrated, and has a rougher texture.

[0047] As discussed above, the composition can reverse the appearance of skin aging by promoting collagen expression and the amount of collagen present in the extracellular matrix of skin.As a result of increasing collagen in the extracellular matrix of skin, the amount and / or appearance of wrinkles can be reduced;skin can look less loose and / or have increased elasticity;and / or skin can look smoother, plumper, and / or more hydrated.

[0048] Thus, the composition can be considered as an "anti-aging" composition in that it can prevent or delay the apparent increase in age of skin.Delayed skin aging can be characterized as delaying the appearance of wrinkles on skin that would otherwise appear if the composition of the present invention had not been applied.Delayed skin aging can also be associated with delaying the rate at which skin loses elasticity, becomes more loose, loses hydration, and / or appears more rough as a result of aging.Similarly, prevention of skin aging can be characterized by preventing the appearance of wrinkles, preventing skin loss of elasticity, preventing skin from becoming more loose, preventing skin hydration loss, and / or preventing skin from becoming more rough as a result of aging.

[0049] The delay or prevention of skin aging may be determined by any known method in the art. For example, the physical characteristics of the skin (e.g. wrinkles, loss of elasticity, increased laxity, decreased hydration, roughness of the skin, etc.) may be measured in a sample group of individuals before one or more applications of the composition, and then the measurements may be repeated after administration of the composition. The physical characteristics of the skin of a control group of individuals may also be measured over the same period as the sample group, and the rate of change in the progression of skin aging may be compared between the two groups. A decrease in the rate of skin aging in the sample group compared to the control group indicates that the composition has delayed or prevented the increase in the apparent age of the skin in the sample group. The delay or prevention of skin aging may also be evaluated by applying the composition to a defined test area of ​​an individual over a period of time. The rate of skin aging in the test area may then be compared to the rate of skin aging in a control area of ​​the same individual that is not exposed to the composition. A decrease in the rate of skin aging in the test area compared to the control area indicates that the composition has slowed or prevented the apparent aging of the skin in the test area.

[0050] The composition may also reduce or reverse the apparent age of skin. "Reversal" of skin aging refers to the reduction in the appearance of characteristics associated with aging skin (e.g. wrinkles, reduced elasticity, increased laxity, reduced hydration, roughness of skin, etc.). Thus, reversal or reduction of skin aging means reducing the apparent age of skin. For example, reduction of the apparent age of skin may be characterized by a reduction in the number of wrinkles present on the skin after applying the composition of the present invention compared to the skin before the composition is applied. Reduction of the apparent age of skin may also be associated with the skin becoming more elastic, less lax, more hydrated, and / or the skin appearing smoother and / or less rough. Reduction or reversal of the apparent age of skin may be measured by comparing the physical characteristics (e.g. number and / or severity of wrinkles, skin elasticity, laxity, roughness, hydration, etc.) of an area of ​​skin before applying the composition to the same area of ​​skin after applying the composition to the skin one or more times. For example, a reduction in the number of wrinkles, increased elasticity, reduced laxity, reduced roughness and / or increased hydration indicate that the composition has reversed or reduced the apparent age of the skin.

[0051] Erythema is a rash caused by injury or inflamed capillaries. Erythema is characterized by redness of the skin in affected areas and may be considered a sign of reduced skin health and / or reduced skin appearance. Erythema may occur as a symptom of skin inflammatory disorders, such as eczema, psoriasis, and irritant contact dermatitis. The composition according to the first aspect of the present invention may improve skin health and / or improve the appearance of the skin by reducing the intensity of the redness associated with erythema. The composition may reduce the redness associated with erythema by reducing the inflammatory response at the affected site. For example, the composition may reduce inflammation by modulating the expression of genes associated with the AP-1 and AP-2 inflammatory pathways and / or the aromatic hydrocarbon receptor pathway.

[0052] In addition to playing a role in regulating inflammation, the aryl hydrocarbon receptor pathway is known to play a role in maintaining the barrier function of the skin and limiting transepidermal water loss, thereby maintaining skin hydration (Haas et al., 2016). The composition according to the first aspect of the present invention thus modulates gene expression of genes associated with the aryl hydrocarbon receptor signaling pathway, thereby improving skin appearance, improving skin health, reversing the appearance of skin aging, or preventing the appearance of skin aging by reducing the level of transepidermal water loss.

[0053] Physiological parameters and characteristics of skin, such as hydration, transepidermal water loss, erythema index, elasticity, erythema, darkness, roughness, extensibility, resistance, radiance, dullness, dryness, pH, pigmentation, are well known in the art and can be found, for example, in Agache, A., 2016. Agache's measuring the skin. Cham: Springer. For example, skin firmness, elasticity and smoothness can be measured using techniques standard in the art, for example, using cutometry. Skin hydration can be determined using a volume meter to determine the water content of the skin and / or by measuring the rate of transepidermal water loss. The degree of redness, dryness, roughness, and wrinkling can be assessed, for example, by visual inspection of the skin by a trained dermatologist.

[0054] The lysate, active fraction, or population may be present in the composition in an amount sufficient to promote keratinocyte proliferation in vitro and in vivo.Standard cell proliferation assays known in the art may be used to determine whether the lysate, active fraction, or population stimulates cell proliferation in vivo.For example, colorimetric techniques, flow cytometry, or imaging may be used to assay the cell proliferation rate in cell populations exposed to the composition compared to cells not exposed to the composition.

[0055] The lysate, active fraction, or population may be present in the composition in an amount sufficient to protect keratinocytes from stimulus-induced cell death in vitro and in vivo. An in vitro stimulation assay, such as the assay described in Example 5, may be used to determine whether the lysate, active fraction, or population is present in an amount sufficient to protect keratinocytes from stimulus-induced cell death. Reduction in cell death may be determined by comparing the rate of cell death in a cell population exposed to a stimulant (e.g., SDS) and a composition of the invention to cells exposed to the stimulant alone.

[0056] The lysate, active fraction, or population may be present in the composition in an amount sufficient to prevent or reduce skin inflammation, such as irritant-induced skin inflammation.This can be evaluated using the model of irritant-induced inflammation described in Example 6.The reduction in irritant-induced inflammation of the skin can be determined by comparing the amount of inflammation observed in a subject exposed to an irritant without exposure to the composition of the present invention.

[0057] In a second aspect, the present invention relates to a cosmetic method comprising applying the composition according to the first aspect to the skin of a subject. The method may improve the appearance of the skin of the subject, compared to the appearance of the skin before application of the composition. Additionally or alternatively, the method may reduce the apparent age of the skin of the subject, compared to the apparent age of the skin before application of the composition. The composition may also be used to prevent or reduce the onset of the increase in apparent age of the skin, compared to the increase in apparent age of the skin when the composition is not applied to the skin.

[0058] The improvement of skin appearance or the reduction of the apparent age of skin may be related to an increase in the apparent plumpness of skin and / or an increase in the smoothness of skin (i.e., skin may appear less wrinkled) compared to the appearance of skin before administration of the composition. The improvement of skin appearance may also be related to a reduction in redness, flaky or roughness of skin compared to the appearance of skin before administration. Skin may also appear more hydrated after administration of the composition compared to the appearance before administration. Methods for measuring skin plumpness, smoothness, redness, flaky, roughness, hydration, and wrinkle severity are well known in the art.

[0059] The administration is preferably an effective amount, which is an amount sufficient to show a benefit to an individual, i.e., an improvement in the appearance of the skin or a decrease in the apparent age of the skin. The composition may be applied to the skin at the discretion of the subject. For example, the composition may be applied between 1 and 10 times per day. The increase in the appearance of the skin or the decrease in the apparent age of the skin may become evident after continued use of the composition for a period of time. For example, the improvement in the appearance of the skin or the decrease in the apparent age of the skin may become evident after continued use of the composition for between 1 day and 1 year.

[0060] In a third aspect, the present invention relates to a composition according to the first aspect for use in a method for treating inflammatory skin diseases, irritant skin diseases, pruritus, genital irritation, balanitis, vaginitis, acne, and / or dermatitis, such as irritant contact dermatitis, atopic dermatitis, eczema, atopic eczema, psoriasis, and / or skin irritation caused by a skin irritant. In a fourth aspect, the present invention relates to a method for treating inflammatory skin diseases, irritant contact dermatitis, atopic dermatitis, eczema, atopic eczema, psoriasis, pruritus, genital irritation, balanitis, vaginitis, acne, and / or skin irritation caused by an inflammatory skin irritant in a subject in need of treatment, comprising administering to the subject a composition according to the first aspect. In some embodiments of the third and fourth aspects, the composition is for use in a method for treating or preventing acne. In some embodiments, the composition comprises a lysate of Lactobacillus crispatus or an active fraction thereof for use in a method for treating or preventing acne. In some embodiments of the third and fourth aspects, wherein the composition comprises a Lactobacillus crispatus population, the composition is not for use in a method of treating or preventing acne.

[0061] In the third and fourth aspects, treatment may include preventing, alleviating or reducing symptoms associated with disease or disorder; and / or preventing the onset or healing of disease or disorder. Atopic eczema may affect any part of the skin, but is most commonly associated with the elbow and knee joints and the creases of the wrist and neck. Coin-sized areas of inflammation on the hands and feet and small projections corresponding to hair follicles are also common in atopic eczema subjects. Affected skin is usually red, dry and itchy. Affected skin may also be oozing, blistering, tough, peeling or thickening.

[0062] Due to the associated itching, subjects with atopic eczema may scratch the affected area, further damaging the skin and causing bleeding. In areas that are repeatedly scratched, the skin may thicken (lichenification), leading to more intense itching and further damage. During periods when atopic eczema is highly active, the affected area may become moist and oozing, and may be associated with the development of small blisters, especially on the hands and feet. Topical administration of the compositions according to the present invention may reduce one or more symptoms associated with atopic eczema. For example, the compositions may reduce inflammation, redness, lichenification (pruritus) or dryness of the affected area. The compositions may also prevent atopic eczema from causing inflammation, redness, itching, or dryness of the skin. Reducing or preventing symptoms associated with atopic eczema may prevent the subject from scratching the skin and further damaging it (e.g., preventing lichenification and / or destruction of the skin barrier). Psoriasis is a common chronic inflammatory skin disorder characterized by heterogeneous clinical signs. Clinical signs include well-delimited symmetric erythema with adjacent silvery scale. Psoriasis Area and Severity Index (PASI) is a quantitative rating score to measure the severity of psoriasis lesions based on coverage and plaque appearance, and can be used to evaluate the severity of symptoms before and after treatment. PASI score considers both plaque characteristics and the area percentage of affected body parts covered by psoriasis lesions. Plaque characteristics can be judged on erythema level, skin induration / thickening, and desquamation. Topical administration of the composition according to the first aspect of the present invention can reduce erythema, skin induration / thickening, desquamation, itching and / or stinging caused by psoriasis lesions. Topical administration of the composition can reduce the total area covered by psoriasis lesions. Thus, topical administration of the composition can reduce the PASI score of the patient.

[0063] Contact dermatitis is a common inflammatory skin condition characterized by erythematous and pruritic skin lesions that occur after contact with a foreign substance. There are two types of contact dermatitis: irritant and allergic. Irritant contact dermatitis is caused by non-immunomodulatory irritation of the skin by a substance, leading to skin changes. Allergic contact dermatitis is a delayed irritant reaction in which a foreign substance comes into contact with the skin; skin changes occur after re-exposure to the substance. The most common substances that cause contact dermatitis include poison ivy, nickel, and fragrances. Contact dermatitis usually leads to erythema and scaling, with a visible border. Itching and discomfort may also occur. Acute cases may involve dramatic inflammation with erythema, vesicles, and blisters; chronic cases may involve lichen with cracks and fissures. Topical administration of the composition can reduce the severity of symptoms associated with contact dermatitis, including erythema, scaling, and itching. Topical administration of the composition can prevent a patient from developing symptoms associated with contact dermatitis, such as preventing the onset of itching, erythema, or scaling.

[0064] Irritant contact dermatitis is characterized by inflammation of the skin due to direct contact with a substance on the skin's surface. It is usually caused by a substance such as a solvent or other chemical that can irritate the skin. Exposure can cause red spots and itching on the affected skin area.

[0065] Irritant contact dermatitis occurs in 80% of all sufferers of contact dermatitis, whereas allergic contact dermatitis occurs in only about 10-20%. This condition involves a combination of intrinsic and extrinsic factors that trigger a pathophysiological cascade of skin barrier disruption, cellular damage to the keratinocyte membrane, and release of proinflammatory mediators resulting in a clinical presentation that may be characterized by erythema, edema, local necrosis beginning shortly after exposure to an irritant, and may develop pustular and acneiform dermatitis. In contrast to allergic contact dermatitis, ICD patients do not develop skin allergies and produce negative results on patch tests. Topical administration of the composition may reduce the severity of symptoms associated with irritant contact dermatitis, including itch and erythema. Topical administration of the composition may prevent patients from developing symptoms associated with irritant contact dermatitis, such as preventing the development of itch or erythema.

[0066] Genital irritation is a common condition that affects both women and men, with a variety of underlying causes, for example, as a result of bacterial or yeast infection or allergic reactions. Vaginitis is a condition in which the vagina becomes infected and / or inflamed. Vaginitis is characterized by stinging and swelling in and around the vagina, which can lead to discomfort and itching (pruritus). Vaginitis can also include inflammation of the vulva (referred to as vulvovaginitis). The term "vaginitis" as used herein is used to include vulvovaginitis. Symptoms of vaginitis include, for example, irritation, pruritus, and erythema. The underlying cause of vaginitis can be bacterial (e.g., chlamydia or gonorrhea), yeast (e.g., candida), viral (e.g., herpes simplex virus or human papilloma virus) or parasitic (e.g., trichomoniasis) infection. Vaginitis can also develop as a result of contact with an allergen, which causes an allergic reaction in and around the vagina. Vaginitis can also be caused by exposure of the vagina to irritants (i.e., a non-allergic reaction).

[0067] Balanitis is a condition in which the glans (head) of the penis becomes inflamed. Patients with balanitis usually present with a red, swollen, itchy and tingling glans. Symptoms of balanitis include pain, tenderness, and pruritus, which may be associated with, for example, erythematous lesions on the glans of the penis and / or the foreskin. The underlying cause of balanitis may be bacterial (e.g., chlamydia or gonorrhea), yeast (e.g., candida), viral (e.g., herpes simplex virus or human papilloma virus), or parasitic (e.g., trichomoniasis) infection. Balanitis may also develop as a result of contact with an allergen, producing an allergic reaction in and around the glans. Balanitis may also be caused by exposure of the glans to irritants (i.e., non-allergic reactions) or through poor hygiene.

[0068] The topical administration of the composition of the present invention to the genitals can reduce the severity of symptoms associated with genital irritation or prevent the onset of symptoms associated with genital irritation.For example, the topical administration of the composition to the vagina can reduce the severity of symptoms associated with vaginitis or prevent the onset of symptoms.For example, after topical administration of the composition to the vagina of a patient suffering from vaginitis, the severity of itching and / or erythema can be reduced.Similarly, the topical administration of the composition to the penis can reduce the severity of symptoms associated with balanitis or prevent the onset of symptoms.For example, after topical administration of the composition to the penis of a patient suffering from balanitis, the severity of itching and / or erythema can be reduced.

[0069] The method includes topical administration of a therapeutically effective amount of the composition to the skin of the subject. The administration is preferably in a "therapeutically effective amount", which is an amount sufficient to show benefit to the individual. The actual amount administered, as well as the rate and time course of administration, will depend on the nature and severity of the disease being treated. For example, the composition may be applied between 1-10 times per day. The composition may also be applied as required by the subject, for example, upon presentation of symptoms (e.g., pruritus) associated with inflammatory skin irritation, irritant contact dermatitis, atopic dermatitis, eczema, atopic eczema, genital irritation, vaginitis, balanitis, or psoriasis.

[0070] Prescription of treatment, such as decisions regarding dosage, is within the responsibility of general practitioners and other physicians, and typically takes into account the disorder being treated, the condition of the individual patient, the site of delivery, the method of administration, and other factors known to physicians. Examples of the techniques and protocols mentioned above can be found in Remington's Pharmaceutical Sciences, 20th Edition, 2000, pub. Lippincott, Williams & Wilkins.

[0071] Those skilled in the art will appreciate that a composition for use according to the third aspect of the invention will comprise the active ingredient and suitable pharmaceutical grade pharma- ceutically acceptable excipients and carriers, if any.

[0072] Pharmaceutical compositions may be prepared using pharma- ceutical "carriers" that are composed of materials that are considered safe and effective. "Pharmaceutical acceptable" refers to molecular entities and compositions that are "generally regarded as safe," e.g., physiologically acceptable, and typically do not produce allergic or similar adverse reactions, e.g., skin irritation, when administered to humans. In some embodiments, the term refers to molecular entities and compositions that are approved by a U.S. federal or state government regulatory agency as listed on the GRAS list or similar list under Sections 204(s) and 409 of the Federal Food, Drug, and Cosmetic Act, the United States Pharmacopeia, or another generally recognized pharmacopoeia, subject to premarket review and approval by the FDA, for use in animals, and more particularly in humans.

[0073] The term "carrier" refers to diluents, binders, lubricants and disintegrants. Those skilled in the art are familiar with such pharmaceutical carriers and how to formulate pharmaceutical compositions with such carriers.

[0074] The pharmaceutical compositions provided herein may include one or more excipients, such as solvents, solubility enhancers, suspending agents, buffers, isotonicity agents, antioxidants, or antimicrobial preservatives. When used, the excipients of the composition do not adversely affect the stability, bioavailability, safety, and / or efficacy of the active ingredient, i.e., the lysate, fraction, and / or population of Lactobacillus crispatus used in the composition. Thus, one skilled in the art will recognize that a composition is provided in which there is no incompatibility between any of the components of the composition. The excipients may be selected from the group consisting of, for example, buffers, solubilizers, isotonicity agents, chelating agents, antioxidants, antimicrobial agents, and preservatives.

[0075] The compositions for use according to the third aspect of the invention may be administered alone or in combination with other treatments, either simultaneously or sequentially depending on the condition to be treated.

[0076] As appropriate, the features disclosed in the foregoing description, or the following claims, or the accompanying figures, expressed in, or with respect to, particular types of means for performing a disclosed function, or methods or processes for obtaining a disclosed result, may be utilized to realize the invention in its various forms, either separately or in any combination of such features.

[0077] While the present invention has been described in conjunction with the above exemplary embodiments, many equivalent modifications and variations will be apparent to those skilled in the art upon presentation of this disclosure. Accordingly, the above exemplary embodiments of the present invention are considered to be illustrative and not limiting. Various changes to the described embodiments may be made without departing from the spirit and scope of the present invention.

[0078] For the avoidance of any doubt, any theoretical explanations provided herein are provided for the purpose of improving the understanding of the reader, and the inventors do not wish to be bound by any of these theoretical explanations.

[0079] Any section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

[0080] Throughout this specification, including the claims which follow, unless the context otherwise requires, the words "comprise" and "include", as well as variations such as "comprises", "comprising", and "including", are understood to indicate the inclusion of a reference integer or step or group of integers or steps, but not the exclusion of any other integer or step or group of integers or steps.

[0081] It should be noted that, as used in the specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. As used herein, ranges may be expressed as "about" one particular value and / or to "about" another particular value. When such a range is expressed, another embodiment includes from the one particular value and / or to the other particular value. Similarly, when a value is expressed as a number by use of the antecedent "about," it will be understood that the particular value forms another embodiment. The term "about" in connection with a numerical value is optional and means, for example, ±10%. EXAMPLES

[0082] Example 1 - Lactobacillus crispatus colonizes the skin of healthy individuals and is lost in atopic eczema and psoriasis

[0083] To identify microbes beneficial for skin function, remodeling and anti-inflammatory potential, skin microbiome datasets were analyzed from over 300 individuals, including healthy volunteers, patients with atopic eczema and psoriasis. Reads from 16S sequencing were aligned using QUIME software. Operational taxonomic units (OTUs) were then integrated with transcriptome data to perform pathway analysis. Differences in taxonomic abundance were assessed by ANOVA statistical tests or by random forest analysis.

[0084] This analysis identified that the microorganism, Lactobacillus crispatus, abundantly colonizes the skin of healthy individuals but is significantly reduced in patients suffering from the skin diseases, atopic eczema and psoriasis (Figure 1A). This data suggests a beneficial function for L. crispatus in the treatment of atopic eczema, psoriasis, and related pathologies, such as dermatitis, skin infections, dry skin, and skin thickening.

[0085] Example 2 - L. crispatus colonizes the skin of young individuals and decreases in older individuals

[0086] The data analysis methodology described above in Example 1 was applied to identify microbes with beneficial anti-aging functions by comparing the symbionts present on the skin of younger (19-25 years old) versus older (44-77 years old) individuals. This analysis revealed that the abundance of L. crispatus on the skin tended to decrease with age, with older healthy individuals exhibiting significantly reduced L. crispatus colonization compared to the skin of younger healthy individuals (Figure 1B). Such correlations suggest a role for L. crispatus in preventing or slowing skin aging.

[0087] Example 3 - L. crispatus is associated with anti-aging and anti-inflammatory pathways

[0088] To study how L. crispatus can positively affect skin function, a separation of healthy donors with 25% high vs. 25% low L. crispatus colonization or no L. crispatus colonization was performed. The genes associated with these two groups were then analyzed by the online analysis tools Reactome and KEGG pathways. This analysis revealed that L. crispatus is associated with pathways related to: collagen formation, collagen biosynthesis and retinol, suggesting a role for L. crispatus in preventing skin aging and remodeling (Figure 2). It was further revealed that L. crispatus regulates pathways involved in anti-inflammatory responses, for example, by controlling gene expression of skin protective transcription factors, aromatic hydrocarbon receptors, and inflammatory pathways AP-1 and AP-2 (Figure 2).

[0089] Example 4 - L. crispatus lysate activates the aryl hydrocarbon receptor pathway

[0090] The transcription factor AhR has been shown to mediate anti-inflammatory and skin protective effects when activated in keratinocytes. To assess whether L. crispatus activates the aryl hydrocarbon receptor, activation of pathways downstream of AhR was assessed in keratinocytes exposed to L. crispatus lysate.

[0091] The cytochrome isoform CYP1A1 and AhR repressor (AhRR) genes are under the direct control of the transcription factor AhR. Primary keratinocytes were treated with L. crispatus lysate in the presence or absence of AhR inhibitors for 12 h, and induction of CYP1A1 and AhRR was assessed by RT-PCR.

[0092] Both CYP1A1 and AhRR were induced by L. crispatus lysate, an effect that was suppressed by the presence of an AhR inhibitor (Figure 3A and Figure 3B). This data suggests that AhR is bound by L. crispatus lysate in keratinocytes and mediates the anti-inflammatory and skin remodeling effects. L. crispatus lysate was also seen to promote keratinocyte proliferation in these assays (data not shown).

[0093] Example 5 - L. crispatus lysate protects keratinocytes from irritant-induced cell death

[0094] Next, we investigated the functional effects of L. crispatus on keratinocytes using an in vitro stimulation model with primary adult human keratinocytes (NHEKs).

[0095] Primary keratinocytes at passages 2–3 were cultured in 96-well plates at a seed concentration of 7000 cells / well and grown in complete keratinocyte medium. Once subconfluent (90–95%), cells were pulsed with L. crispatus lysate or active components for 2 h. After 2 h preincubation, cells were treated with SDS. After 2 h, MTT was added to the cultures and incubated for an additional 2 h, for a total incubation time of 6 h. After incubation, the MTT assay was developed and OD was measured in a 96-well plate reader to determine keratinocyte viability, according to the manufacturer's instructions.

[0096] Treatment with SDS alone in the irritation model was shown to be highly toxic, resulting in 0% viability after 6-8 hours of incubation with SDS (Figure 4A). Pretreatment with L. crispatus lysate dramatically improved viability, with an average viability of 70% compared to control cells. These data suggest that L. crispatus lysate protects skin cells against irritant-mediated cell death.

[0097] To compare the strength of L. crispatus lysate to commonly used skin care actives, L. crispatus lysate was compared to commercially available panthenol, Centella asiatica, Lactobacillus ferment lysate, colloidal oatmeal, and ceramides in an in vitro irritant test. L. crispatus, but not any of the other actives, protected keratinocytes from SDS-induced cell damage (Figure 4B).

[0098] These data suggest that L. crispatus lysate has superior potency in protecting keratinocytes from cellular damage and that its mechanism of action is different from other active ingredients or components.

[0099] Example 6 - Lactobacillus crispatus lysate reduced SDS-induced inflammation in the skin of healthy volunteers and showed no irritant profile

[0100] To evaluate whether L. crispatus lysate has a significant skin protective function in vivo, skin irritation tests were performed in healthy volunteers.

[0101] Each animal was treated with the following solutions: Solution 1: SDS 4% containing SDS dissolved in PBS Solution 2: L. crispatus lysate diluted 1:2 from the original preparation containing SDS 4% Solution 3: L. crispatus lysate diluted 1:2 from the original preparation.

[0102] The same amount of each solution is added to 1 cm 2 The solution was then applied to a bandage measuring 1.0 mm in diameter. The bandage containing the solution was then applied in an occlusive manner to the forearm of a healthy donor to increase the penetration of the solution into the skin. 24 hours after application, the bandage was removed, photographs were recorded, and irritation was assessed by a blinded dermatologist.

[0103] SDS alone induced skin inflammation in all individuals, characterized by erythema and immune cell infiltration in the skin (Figure 5). L. crispatus lysate strongly reduced the SDS inflammatory response in 5 / 7 test subjects. Conversely, L. crispatus lysate alone did not induce any skin irritation in any of the test subjects, suggesting that the lysate is a non-irritant.

[0104] Taken together, these data suggest a strong anti-inflammatory and skin protective effect of L. crispatus lysate in human skin.

[0105] Example 7 - Lactobacillus crispatus promotes the resolution of skin inflammation and reduces pruritus

[0106] To evaluate whether L. crispatus lysate has a significant anti-inflammatory function in skin disorders, volunteers suffering from eczema, irritant dermatitis, genital irritation, and genital balanitis were treated with a topical composition containing L. crispatus lysate. All volunteers applied the composition to the affected areas of the skin 1-3 times per day. All volunteers (100%) reported improvement in skin condition, redness, and associated pruritus within 24 hours of application. Taken together, these data suggest anti-inflammatory and anti-pruritic activity of L. crispatus lysate in multiple skin disorders.

[0107] References In order to more fully describe and disclose the present invention and the state of the art to which it pertains, several publications are cited. Full citations for these references are provided below. Each of these references is incorporated herein by reference in its entirety.

[0108] Agache, A., 2016. Agache's measuring the skin. Cham: Springer Gottschalck, T. and McEwen, G., 2004. International cosmetic ingredient dictionary and handbook. Washington, D.C.: Cosmetic, Toiletry, and Fragrance Association. Harry, R. and Rieger, M., 2000. Harry's cosmeticology. New York: Chemical Pub. Co. Haas, K., Weighardt, H., Deenen, R., Kohrer, K., Clausen, B., Zahner, S., Boukamp, P., Bloch, W., Krutmann, J. and Esser, C., 2016. Aryl Hydrocarbon Receptor in Keratinocytes Is Essential for Murine Skin Barrier Integrity. Journal of Investigative Dermatology, 136(11), pp.2260-2269 Moore & Holdeman, 1970 (Brygoo & Aladame, 1953) Lactobacillus crispatus in GBIF Secretariat (2021). GBIF Backbone Taxonomy. Checklist dataset https: / / doi.org / 10.15468 / 39omei accessed via GBIF.org on 2021-11-04. Remington, J. and Gennaro, A., 2000. Remington the science and practice of pharmacy. Baltimore, Md.: Lippincott Williams & Wilkins. Williams, D. and Schmitt, W., 1996. Chemistry and Technology of the Cosmetics and Toiletries Industry. Dordrecht: Springer Netherlands. For standard molecular biology techniques, see Sambrook, J., Russell, DW Molecular Cloning, A Laboratory Manual. 3 ed. 2001, Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press.

Claims

1. 1. A composition for topical administration comprising: A lysate of Lactobacillus crispatus or an active fraction thereof; and / or Lactobacillus crispatus population Including; The lysates, active fractions and / or populations are present in an amount effective to improve the appearance of the skin compared to the skin prior to administration of the composition, improve the health of the skin, prevent or treat skin inflammatory disorders, prevent or treat skin irritation, prevent or reduce skin pruritus, prevent or treat genital irritation, vaginitis or balanitis, treat or prevent acne, slow or prevent skin aging, and / or reduce the apparent age of the skin compared to the skin prior to administration of the composition. composition.

2. 10. The composition of claim 1, further comprising one or more physiologically acceptable carriers, excipients, preservatives, fillers, anti-caking agents, anti-foaming agents, bulking agents, thickening agents, gelling agents, emulsifiers, surfactants, film formers, propellants, pH adjusters, neutralizing agents or stabilizers.

3. 3. The composition of claim 2, wherein the one or more excipients are selected from isopropanol, hydroxypropyl cellulose, glyceryl stearate, cetyl stearyl alcohol, glycerol, cetyl alcohol liquid petrolatum, isopropyl myristate, methyl POB, propyl POB.

4. 10. The composition of any one of the preceding claims, further comprising one or more physiologically acceptable active agents selected from astringents, antioxidants, antimicrobial agents, antifungal agents, chelating agents, topical analgesics, anti-aging agents, anti-wrinkle agents, skin lightening agents, skin conditioning agents, anti-irritants, anti-inflammatory agents, anti-cellulite agents, emollients, sunscreens, self-tanning agents, biologically active peptides.

5. 10. The composition according to any one of the preceding claims, wherein the composition is in the form of a cream, lotion, gel, mousse, solid stick, spray, ointment, or milk.

6. The composition of any one of the preceding claims, wherein the lysate, active fraction, or population is present in an amount sufficient to alter expression of genes involved in one or more of collagen biosynthesis, collagen formation, extracellular matrix organization, collagen chain trimerization, aromatic hydrocarbon signaling, anti-apoptotic molecules, cell proliferation and inflammation when applied to skin cells, keratinocytes, fibroblasts and skin immune cells in vitro or in vivo.

7. A composition according to any one of the preceding claims, wherein the population, lysate or active fraction thereof is present in an amount sufficient to activate the aryl hydrocarbon receptor pathway when applied to skin cells, keratinocytes, fibroblasts and skin immune cells in vitro or in vivo.

8. The composition of any one of the preceding claims, wherein the lysate, fraction, or population is present in an amount sufficient to promote keratinocyte proliferation in vitro or in vivo, protect keratinocytes from irritation-induced cell death in vitro or in vivo, or prevent or reduce irritation-induced inflammation of the skin.

9. 10. The composition of any one of the preceding claims, wherein the lysate is at a concentration of 0.0001% to 100% by weight, 0.001% to 75% by weight, 0.01% to 50% by weight, or 0.1% to 25% by weight, relative to the total weight of the composition.

10. 10. The composition of any one of the preceding claims, wherein the population is at a concentration of 0.0001% to 100% by weight, 0.001% to 75% by weight, 0.01% to 50% by weight, or 0.1% to 25% by weight, relative to the total weight of the composition.

11. 10. A cosmetic method comprising applying to the skin of a subject a composition according to any one of the preceding claims: i) improving the appearance of the skin compared to the appearance of the skin prior to application of the composition; ii) Improve skin health iii) preventing or reducing skin irritation; iv) preventing or reducing pruritus; v) preventing or reducing genital irritation, including vaginitis and balanitis; vi) preventing or reducing acne; and / or vii) Slowing and / or reversing skin aging method.

12. Skin appearance: a) increasing the firmness, plumpness, smoothness and hydration of the skin; and / or b) Reduce redness, flaking, and / or roughness of the skin The cosmetic method according to claim 11, wherein the cosmetic effect is improved by

13. i) improves skin health; ii) Preventing or treating skin irritation iii) preventing or treating skin irritation; iv) preventing or treating pruritus; v) preventing or treating genital irritation, vaginitis or balanitis; vi) preventing or treating acne; and / or vii) delaying or preventing skin aging or reversing the apparent aging of the skin compared to the skin prior to administration of said composition; A composition according to any one of claims 1 to 10 for use in a method comprising: The method comprises topically administering to the skin of a subject in need thereof a therapeutically effective amount of the composition.

14. 11. A method of treating a subject with the composition of any one of claims 1 to 10, wherein the composition improves the health of the skin; prevents or treats skin inflammation, skin irritation; prevents or treats pruritus; prevents or treats genital irritation, vaginitis or balanitis; treats or prevents acne, prevents or slows skin aging or reduces the apparent age of the skin compared to the skin prior to administration of the composition.

15. 15. The composition for use according to claim 13 or the method according to claim 14, wherein the subject has an inflammatory skin disease, an irritant skin disease or dermatitis.

16. 16. The composition or method for use of claim 15, wherein the inflammatory skin disease or dermatitis is irritant contact dermatitis, atopic dermatitis, eczema, atopic eczema, psoriasis, and / or skin irritation caused by inflammatory skin irritants.

17. The cosmetic method of claim 11 or 12, the composition for use of any one of claims 13, 14 or 15, or the method for treating a subject of claim 14, wherein the composition modifies expression of genes involved in one or more of collagen biosynthesis, collagen formation, extracellular matrix organization, collagen chain trimerization, aromatic hydrocarbon signaling, anti-apoptotic molecules, cell proliferation and inflammation.

18. 18. The cosmetic method, composition for use, or method for treating a subject according to claim 17, wherein the composition increases expression of genes involved in one or more of collagen biosynthesis, collagen formation, extracellular matrix organization, collagen chain trimerization, aromatic hydrocarbon signaling, anti-inflammatory or anti-apoptotic molecules, and / or decreases expression of pro-inflammatory molecules.

19. 19. The cosmetic method, composition for use, or method for treating a subject according to claim 17 or 18, wherein the composition activates the aromatic hydrocarbon receptor pathway.

20. 11. A method for modifying expression of genes involved in one or more of collagen biosynthesis, collagen formation, extracellular matrix organization, collagen chain trimerization, aromatic hydrocarbon signaling, anti-apoptotic molecules, cell proliferation and inflammation in a subject, comprising topical administration of a composition according to any one of claims 1 to 10.

21. A method for activating the aromatic hydrocarbon receptor pathway in a subject, comprising topical administration of a composition according to any one of claims 1 to 10.

22. 22. The method of claim 20 or 21, wherein the subject is a human.